by Jon Fleetwood,Jon Fleetwood:
Hydrogel forms a “depot” under the skin, slowly releasing vaccine components for weeks.
Researchers at Stanford University, funded by the Bill & Melinda Gates Foundation with lab infrastructure funded by the U.S. National Institutes of Health (NIH), have developed an injectable hydrogel vaccine platform designed to remain in the body and slowly release vaccine components for weeks, including formulations tested using H5N1 avian influenza (“bird flu”) antigens.
TRUTH LIVES on athttps://sgtreport.tv/
The move comes amid state-level, national, and international bird flu pandemic orchestration.
The technology relies in part on Pluronic F-127 (poloxamer 407), a polymer capable of forming a gel deposit after injection.
Scientific literature examining this same polymer shows that when it was used as a delivery medium in animal experiments, it dramatically increased the lethality of inflammatory toxins—reducing the lethal dose (LD50) of bacterial endotoxin in mice by roughly 10–15-fold, meaning animals were far more likely to die from the toxin when the polymer was present (see more on this below).
The hydrogel vaccine platform is described in the study “Enabling Global Access to Potent Subunit Vaccines with a Simple and Scalable Injectable Hydrogel Platform,” published in January in the Royal Society of Chemistry’s peer-reviewed journalBiomaterials Science.
The work was led byEric A. Appel, a materials scientist at Stanford University, along with collaborators across multiple Stanford biomedical research programs.
According to the paper, the system forms a hydrogel depot in tissue after injection, allowing vaccine components to remain localized and be released gradually over time.
Source: SGT Report
